HIV Mutation Detail Information

> T215Y Search Result


Mutation Information
Mutation Site T215Y
Mutation Type Amino acid level
Gene/Protein/Region Type RT
Literature Information
PubMed PMID 30544247
Disease HIV infection/AIDS
Published Year 2019
Journal The Journal of antimicrobial chemotherapy
Title Virological outcomes of boosted protease inhibitor-based first-line ART in subjects harbouring thymidine analogue-associated mutations as the sole form of transmitted drug resistance.
Author Geretti AM,White E,Orkin C,Tostevin A,Tilston P,Chadwick D,Leen C,Sabin C,Dunn DT,UK HIV Drug Resistance Database and UK CHIC Study.
Evidence Most (203 of 269, 75.5%) had singleton TAMs, commonly a revertant of T215Y or T215F (112 of 269, 41.6%). Over a median of 2.5 years of follow-up, 834 of 6599 (12.6%) subjects experienced viraemia (HIV-1 RNA >50 copies/mL). The adjusted HR for viraemia was 2.17 with PI/b versus NNRTI-based therapy (95% CI 1.88-2.51;P < 0.001).

Contents
Description
Mutation Information Note
  • Gene/Protein/Region Type: Virus Gene (e.g. LMP-1) or Virus Protein (e.g. Rep 68) or Virus Region (e.g. S, X)
Literature Information Note
  • Evidence: sentence contains this mutation information in the citation